Lisata Q2 net loss $4.0M, extends cash runway to Q1 2026; tech transfer deal for TPN platform

LISATA THERAPEUTICS, INC.

2023-Q2 EPS reported -$1.28

Net loss $4.0M in Q2 2023 vs $6.6M in Q2 2022, down 40% due to $2.2M NJ tax credit.
Cash and securities $57.6M; projected runway into Q1 2026 based on capital conservation measures.
Signed technology transfer agreement for TPN platform with Impilo Therapeutics; receives equity stake, no future capital commitment.
LSTA1 progress: ASCEND Phase 2b enrollment >70% target; BOLSTER trial open; iLSTA initiated in Australia.
FDA granted orphan designation for LSTA1 in malignant glioma; GBM trial planned for Q4 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LISATA THERAPEUTICS, INC. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-23-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.